Immunotherapy, which is used in cancer treatment to block the immune checkpoints such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1(PD-L1), has shown persisting clinical responses and prolonging survival Feng et al. (2017). Here, PDCD1 is linked to cancer.